Quantification of the biodistribution [111In]In-anti-ICAM-1 and [111In]In-mIgG2a showed significantly higher uptake in PSN-1 tumour xenografts of the former compared to the latter, at 72 h post administration (19.9 ± 1.2 versus 6.9 ± 0.5%ID/g; P < 0.0001) (Fig. 3A). Here, ICAM1 is linked to neoplasm.